Skip to main content
Advertisement
Advertisement
DFTX
DFTX logo
Definium Therapeutics, Inc. Common Shares
28.34
USD
Sponsored
-1.14
-3.87%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

28.33

-0.01
-0.05%

Definium Therapeutics, Inc. Common Shares (DFTX) Earnings

DFTX Earnings Reports

Positive Surprise Ratio

DFTX beat 1 of 5 last estimates.

20%

Next Report

Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.52
Implied change from Q3 26 (Revenue/ EPS)
--
/
+40.54%
Implied change from Q4 25 (Revenue/ EPS)
--
/
+4.00%

Definium Therapeutics, Inc. Common Shares earnings per share and revenue

On Nov 09, 2026, DFTX reported earnings of -0.37 USD per share (EPS) for Q3 26, beating the estimate of -0.56 USD, resulting in a 34.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.12% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an increase of 40.54% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Definium Therapeutics, Inc. Common Shares reported EPS of -$0.37, beating estimates by 34.89%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.12%, changed from $35.39 before the earnings release to $34.64 the day after.
The next earning report is scheduled for Feb 24, 2027.
Based on -- analysts, Definium Therapeutics, Inc. Common Shares is expected to report EPS of -$0.52 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement